Results 261 to 270 of about 1,261,128 (384)

Phenotypic patterns of metabolic dysfunction‐associated steatotic liver disease in type 2 diabetes: The impact of insulin

European Journal of Clinical Investigation, EarlyView.
Abstract Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) often leads to hepatic insulin resistance (IR), yet its link to liver‐specific insulin‐mediated glucose uptake (IGLU) in type 2 diabetes (T2D) remains unclear. We aimed to explore this MASLD‐T2D relationship, addressing organ‐specific IR for personalized management and
Queralt Martín‐Saladich, Rafael Simó, Andreea Ciudin, Julia Baguña, Clara Ramirez‐Serra, Santiago Aguadé‐Bruix, Albert Roque, Maria N. Pizzi, Hug Cuéllar, Nuria Roson‐Gradaille, Miguel A. González Ballester, Juan M. Pericàs, José Raul Herance   +12 more
wiley   +1 more source

Advances in intrahepatic and extrahepatic vascular dysregulations in cirrhotic portal hypertension. [PDF]

Front Med (Lausanne)
Li Y, Zhu B, Shi K, Lu Y, Zeng X, Li Y, Zhang Q, Feng Y, Wang X.   +8 more
europepmc   +1 more source

The Surgery of Portal Hypertension [PDF]

Postgraduate Medical Journal, 1950
openaire   +4 more sources

Autoimmunity in MASLD: Focus on autoantibodies, anti‐apolipoprotein A1 IgG and G protein‐coupled receptors

European Journal of Clinical Investigation, EarlyView.
This review outlines the potential role of anti‐GPCR autoantibodies in MASLD/MASH, given their involvement in a wide range of diseases and their possible contribution to MASLD/MASH pathophysiology. We also focused on anti‐ApoA1 autoantibodies, sharing functional features with anti‐GPCR autoantibodies and have been shown to promote liver steatosis in ...
Sabrina Pagano, Emmanuel Somm, François R. Jornayvaz, Nicolas Vuilleumier   +3 more
wiley   +1 more source

Non-invasive assessment of portal hypertension: Liver stiffness and beyond. [PDF]

JHEP Rep
Mandorfer M, Abraldes JG, Berzigotti A.
europepmc   +1 more source

Cirrhotic portal hypertension: Morbidity of continued alcoholism

, 1978
Narayan V. Pande, Robert H. Resnick, William F. H. Yee, Volker F. Eckardt, Jonathan L. Shurberg   +4 more
openalex   +1 more source

Shear‐wave elastography of the liver and spleen identifies clinically significant portal hypertension: A prospective multicentre study

Liver international (Print), 2017
C. Jansen, C. Bogs, W. Verlinden, M. Thiele, Philipp T. Möller, J. Görtzen, J. Lehmann, T. Vanwolleghem, L. Vonghia, M. Praktiknjo, Johannes Chang, A. Krag, C. Strassburg, S. Francque, J. Trebicka   +14 more
semanticscholar   +1 more source

Portal Hypertension [PDF]

Proceedings of the Royal Society of Medicine, 1963
openaire   +3 more sources

Effectiveness and safety of antithrombin for treatment of portal vein thrombosis: Nationwide prospective surveillance of 4 years of clinical experience in Japan

Hepatology Research, EarlyView.
Abstract Aim Antithrombin (AT), a plasma protein with anticoagulant properties, has a long‐standing medical history, primarily for treatment of congenital AT deficiency. Accumulated clinical experiences suggest AT is a potential anticoagulant for thrombotic diseases. This study aimed to clarify the effectiveness, safety, and clinical significance of AT
Shoichi Matsutani, Makoto Arakawa, Susumu Nakano   +2 more
wiley   +1 more source

Genetic association analysis between LDL-c lowering drugs and portal hypertension using Mendelian randomization analysis. [PDF]

Sci Rep
Xiao QA, Li XL, Qin L, Zhang XL.
europepmc   +1 more source